iLobby Financial Model
Biotech/Pharma Startup Financials (Free Excel Download)
Enterprise Visitor Management (EVM) SaaS platform that digitises, screens, and monitors physical access across facilities for regulated industries.
professionals from Deloitte
Used by professionals from






About this model
iLobby provides visitor-management software for security-sensitive and regulated facilities. The core system handles sign-in, ID scans, watchlist checks, badges, and emergency evacuation, with modules for deliveries, COVID screening, touchless sign-in, temperature checks, facial verification, and employee access.
Subscriptions are charged per entry point monthly: $199 for Corporate, $275 for Enhanced, and $499 for Enterprise. iLobby supplies and owns the kiosk hardware, although the deck does not clarify whether it is embedded in subscription margin or billed as a setup item. Direct sales are primary, with resellers a future lever.
The company had more than 700 clients and 2,500 entry points across 45 countries and 35-plus languages, with logo CAGR of 52% from FY2018–20. It added 239 customers in FY2020. The model should forecast sites, tier mix, hardware cost, implementation, expansion, churn, and support.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
About iLobby
ilobby.com
How to build a detailed financial model for iLobby
A complete walkthrough of the business, drivers, and assumptions behind the downloadable iLobby model - distilled from its pitch deck and publicly available information.
Product & value proposition
Physical facility access management for security-sensitive, compliance-heavy industries. Core platform: Visitor Management (sign-in, ID scanning, watchlist checks, badge printing, emergency evacuation). Add-on modules launched FY2020–FY2021:
- iLobby Delivers (mail/package management, Feb 2020)
- COVID-19 Workflows (pre-screening questionnaire, Apr 2020)
- Touchless Sign-In (mobile-based sign-in, Jun 2020)
- FeverCheck (contactless temperature at sign-in, Jul 2020)
- FaceMatch (facial verification / bypass, Sep 2020)
- Employee Pass Mobile App (daily sign-in/out, door locking, Oct 2020)
Differentiators: multi-platform kiosk support (iOS, Android, Windows), one-stop-shop (iLobby owns and ships hardware), white-glove enterprise support, watchlist integrations (ITAR, C-TPAT), SOC-2 / GDPR / FISMA compliant.
Market
Bottom-up TAM analysis (enterprise tier only, full entry-point penetration at current pricing, CAD/USD 1.32):
| Segment | Employee range | Companies worldwide | Avg entry points | Monthly price/entry point | TAM |
|---|---|---|---|---|---|
| Extra Large | >50K | 2,083 | 100 | C$659 | ~C$1.6B |
| Large | 10K–50K | 10,090 | 50 | C$659 | ~C$3.9B |
| Medium | 2K–10K | 50,963 | 30 | C$363 | ~C$6.7B |
| Small | 1K–2K | 54,982 | 10 | C$263 | ~C$1.7B |
| Total TAM | - | - | - | - | ~C$14.0B |
Notes: Company count sourced from S&P Capital IQ; entry points per company are management estimates. Companies <1,000 employees excluded.
Growth rate of market: Not quantified in deck. Qualitative commentary: "Increasing importance of EVM in a post-COVID world is driving accelerated adoption."
Revenue model
Subscription SaaS per entry point per month, three tiers:
- Corporate: US$199 / entry point / month
- Enhanced: US$275 / entry point / month
- Enterprise: US$499 / entry point / month
Three packages referenced in slide 5; mapping to the above three price points is - likely Corporate = entry-level, Enhanced = mid, Enterprise = full-featured.
Hardware: iLobby owns the hardware and provides it as part of the solution (all-inclusive / one-stop-shop). Revenue treatment (bundled in subscription vs. separate HW revenue) not stated.: Hardware cost embedded in subscription margin or a one-time setup fee.
Channels: Direct sales (4 new sales hires in FY2020); VAR/reseller model identified as a growth lever but not yet the primary channel.
Traction & metrics
- 700+ clients
- 2,500+ entry points deployed globally
- 45 countries
- 35+ languages
- 52% CAGR in Logos from FY2018–FY2020
- 239 new customers added in FY2020; key adds: Comcast, Concord Foods, Labatt Brewing, Vancouver Fraser Port Authority
- Fiscal year end: July 31
- Original Visitor Management release: FY2018; most recent platform update: January 2020
Revenue, ARR, MRR, EBITDA, churn, NRR: Not in deck. This CIP appears to be a teaser; detailed financials would be in a separate dataroom package.
Unit economics
Implied ARPA (rough sanity check using deck data - tagged):
- 700 clients, 2,500 entry points → ~3.6 entry points per client on average
- At blended price ~US$275/entry/month × 3.6 × 12 ≈ US$11,900 ARPA/year per client
- At enterprise tier (US$499): ~US$21,500/year per client
Competition / moat
Named competitors implied via comparison matrix (slide 9): positioned against office-focused EVM players (SMB/mid-market). iLobby wins on:
- Robust suite of functions
- Scalable SaaS platform
- Wide-ranging platform integrations
- Cutting-edge features
- Focused on industrial/commercial sectors less impacted by COVID (vs. office-first competitors)
Moat claims:
- High switching costs for large enterprise (organizational complexity, integration depth)
- Owns hardware - controls procurement and deployment
- Regulatory integrations (ITAR, C-TPAT, government watchlists) are expensive to replicate
- 25+ years of security expertise (founding team heritage)
Team & funding ask / use of funds
CEO: Ariel Mashiyev - joined August 2017, led restructuring. Awards: 2019 OBAA Young Entrepreneur of the Year; 2018 Startup Canada Ontario Region High-Growth Entrepreneurship.
Founding/prior team: Security industry veterans (25+ years of security experience referenced).
Transaction: RBC Capital Markets engaged as sole financial advisor for potential share sale. No specific raise amount, use of funds, or valuation disclosed in this CIP.
Recommended financial model
- Archetype + why: SaaS ARR / entry-point subscription model with 3-statement build.
- Revenue unit is the entry point (not seat, not user), billed monthly. Three pricing tiers drive blended ARPA.
- Hardware component needs a treatment (capex owned by iLobby, depreciated, or bundled in subscription COGS).
- This is a growth equity / strategic sale process (CIP via RBC), so the model should reflect a buyer/investor perspective: LTM actuals + 3–5 year forecast with EBITDA bridge and exit multiple.
- Forecast horizon & granularity: Monthly for Year 1–2; quarterly/annual for Years 3–5. FY end July 31.
- Key drivers & assumptions:
| Driver | Value | Source | | -- | -- | -- | | Entry points at period start | 2,500 | - | | Logo count at period start | 700 | - | | Logo CAGR (FY2018–FY2020) | 52% | - | | Avg entry points / logo | ~3.6 | - | | Blended price / entry point / month | US$263–499 (3 tiers) | - | | New logo growth rate (forecast) | 30–40% | - | | Net revenue retention / upsell | ~110–120% | - | | Gross margin % | 65–75% | - | | Hardware cost per entry point | : ~US$500–800 one-time, capitalized | iLobby owns hardware - amortized over contract term | | Sales headcount growth | 4 added in FY2020 | ; further expansion in forecast | | CAC payback period | 18–24 months | - | | Churn rate (logo) | 5–8% annually | - |
- Scenarios (Base / Bull / Bear - which variables flex):
- Base: Logo growth 30% YoY, blended ASP stable, NRR 110%, GM 70%
- Bull: Logo growth 50% (COVID tailwind extends), add-on penetration drives NRR to 120%, gross margin expansion to 75%
- Bear: Logo growth 15% (competition intensifies, macro slowdown), churn rises to 10%, hardware costs squeeze GM to 60%
- Flex variables: new logo growth rate, blended ASP / tier mix, NRR, hardware cost per entry point, sales efficiency (magic number)
- Required sheets / outputs:
- Assumptions - all drivers in one editable block
- Revenue Build - logo cohorts × avg entry points × blended price → MRR/ARR by tier; expansion from add-ons
- Income Statement - Revenue, COGS (SaaS hosting + hardware depreciation), Gross Profit, S&M, R&D, G&A, EBITDA
- Balance Sheet - simplified; focus on hardware asset balance (PP&E), deferred revenue, working capital
- Cash Flow Statement - OpCF, capex (hardware procurement), FCF
- KPI Dashboard - ARR, logo count, entry points, ARPA, NRR, LTV:CAC, EBITDA margin
- Valuation / Exit - ARR multiple range (e.g. 8–15×) → equity value; sensitivity table (ARR × multiple)
Frequently asked
Is the iLobby financial model free?+
Yes. The iLobby model is a free Excel (.xlsx) download with live formulas. Sign up with your email and the workbook is yours to keep, review, and edit.
What's included in the model?+
A 5-year monthly forecast with P&L, cash flow and runway, valuation (exit multiple plus a DCF cross-check), MOIC/IRR returns, and unit economics, with live formulas throughout.
How was this model built?+
It was built from iLobby's pitch deck and publicly available information, then structured to investment-banking standards as a fully editable Excel model.
Can I change the assumptions?+
Yes. You can change assumptions and the live formulas will recalculate in the downloadable Excel model.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Biotech/Pharma Startup Financial Models
Browse another startup in the same category.

Ada Health
AI-powered symptom assessment app and clinical decision-support platform for consumers and healthcare partners.
Affini-T
Engineered T cell therapies targeting oncogenic driver mutations (KRAS, p53) in hard-to-treat solid tumors

Alto Pharmacy
Alto Pharmacy is a tech-enabled, same-day prescription delivery pharmacy disrupting the $450B US pharmacy market via a direct-to-patient courier model and provider-facing software platform.

Aphea.Bio
Aphea.Bio is a Belgian ag-biotech company developing and commercialising microbial biologicals (biostimulants, biofungicides, bioherbicides, bioinsecticides) for row crops, targeting yield improvement and reduced synthetic input use.

Aurion Biotech
Cell therapy company developing an injectable corneal endothelial cell treatment to restore vision in patients with corneal endothelial disease.

Beckley Psytech
Clinical-stage psychedelic drug development platform advancing a pipeline of psychedelic compounds (psilocybin, 5-MeO-DMT, NCEs) as licensed pharmaceutical medicines for neuropsychiatric disorders.

BrightInsight
Regulated digital health platform-as-a-service for biopharma and medtech companies to build, launch, and maintain compliant connected-drug and medical-device software products.
Carrum Health
Value-based care marketplace connecting self-insured employers to top-tier surgical and oncology Centers of Excellence (COEs) via all-inclusive bundled payments.

